AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03285672
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1
Trial: NCT01006460
Drug: Rhodiola rosea, L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Capsules twice a day
Trial: NCT01006460
Drug: Placebo - dark brown sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules twice a day
Trial: NCT00902668
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01999153
Drug: 20 mL topically used during alginate dressing NAROPEINE
RxNorm normalized name: DRESSING,ALGINATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL topically used during alginate dressing
Trial: NCT01999153
Drug: 20 mL topically used during alginate dressing NaCl
RxNorm normalized name: DRESSING,ALGINATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL topically used during alginate dressing
Trial: NCT02024529
Drug: 4 mL Injection of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL Injection of Placebo
Trial: NCT00100178
Drug: Mycophenolate mofeteil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00100178
Drug: Placebo control for Mycophenolate mofeteil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo pills taken orally
Trial: NCT00491764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 24 weeks.
Trial: NCT01691274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, twice a day, 14 days
Trial: NCT03660345
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ziv-Aflibercept
Trial: NCT01108120
Drug: continuous intra-femoral thrombolysis group
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
Trial: NCT01108120
Drug: Conventional therapy group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
Trial: NCT00648856
Drug: Zoloft® Tablets 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fed
Trial: NCT00881673
Drug: AL38583 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic
Trial: NCT00881673
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL38583 Vehicle
Trial: NCT01604044
Drug: Meropur 150 a day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one subcutaneous injection a day
Trial: NCT03385096
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
Trial: NCT01680887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03239184
Drug: Life information rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Trial: NCT00004006
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004006
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02660190
Drug: hexaminoavolunate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00682721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo two pills once daily
Trial: NCT00322556
Drug: Immunoglobulins Intravenous (Human)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
Trial: NCT00751218
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, once daily for 28 days
Trial: NCT03428607
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6738 160mg QD
Trial: NCT03678883
Drug: Doxorubicin.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
Trial: NCT03269669
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03269669
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01318642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
Trial: NCT04155697
Drug: 2% Chlorohexidine Gluconate soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
Trial: NCT04155697
Drug: 62% ethyl alcohol-based hand sanitizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
Trial: NCT00731016
Drug: Zoledronic acid, pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~* injection 1, S1: 0.0125 mg/kg of zoledronic acid~* injection 2, S6: 0.025 mg/kg of zoledronic acid~* injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid
Trial: NCT04466176
Drug: Test Product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT04466176
Drug: Reference Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT04527471
Drug: Placebo pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo delivered twice daily via pMDI
Trial: NCT02344862
Drug: FYU-981 High dose, (Oral daily dosing for 8 weeks)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
Trial: NCT02344862
Drug: FYU-981 Middle dose, (Oral daily dosing for 8 weeks)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
Trial: NCT02344862
Drug: FYU-981 Low dose, (Oral daily dosing for 8 weeks)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
Trial: NCT02344862
Drug: Placebo, (Oral daily dosing for 8 weeks)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the placebo arm receive placebo.
Trial: NCT00658008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, oral, placebo bid, 8 weeks with 2 week taper
Trial: NCT03972982
Drug: Simplified intensive insulin therapy regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
Trial: NCT01266174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match eltoprazine
Trial: NCT02971410
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03277690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole.
Trial: NCT04562467
Drug: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
RxNorm normalized name: ICOSAPENT ETHYL 1000 mg ORAL CAPSULE [Vascepa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 1g capsules BID as per REDUCE-IT
Trial: NCT00416546
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04110678
Drug: NeuroEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroEPO \[CIMAB S.A, Havana, Cuba\]
Trial: NCT01719978
Drug: 3.6mL 2% Mepivacaine with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic with vasoconstrictor
Trial: NCT01719978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mL 0.9% saline administration concomitant to the local anesthetic
Trial: NCT01117948
Drug: Lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
Trial: NCT01117948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
Trial: NCT02592122
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03893175
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Trial: NCT03893175
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Trial: NCT03893175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By mouth
Trial: NCT00493532
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg iv every 3 months
Trial: NCT04047576
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
Trial: NCT04124653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of placebo
Trial: NCT00294801
Drug: flex-a-new (food supplement)
RxNorm normalized name: Ed Flex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02380001
Drug: Dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
Trial: NCT00295854
Drug: MN-001 BID
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients received 500 mg MN-001 bid
Trial: NCT00295854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients received placebo
Trial: NCT03800173
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo IV infusion
Trial: NCT00936611
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04893148
Drug: IGlarLixi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changing to iGlarLixi from insulin glargine
Trial: NCT01074372
Drug: REGN727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cohorts (dose 1, 2, 3, 4)
Trial: NCT01501695
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mimetic granule: same with 5LGr mimetic tablet: same with tiapride
Trial: NCT02259842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03051256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
Trial: NCT01074372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cohorts (dose 1, 2, 3, 4)
Trial: NCT04272359
Drug: Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~* efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~* effects on BMI, blood pressure monitoring and hypoglycemic risk;~* changes in renal function and microalbuminuria;~* tolerability and side effects of the new therapeutic regimes;~* therapeutic adherence;~* post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~* effects on chronic complications of diabetes and cardiovascular safety.
Trial: NCT04295772
Drug: DOR/ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
Trial: NCT02608203
Drug: [68Ga]-DOTANOC PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01103037
Drug: QAV680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAV680 500 mg (5 x 100 mg capsules) four times per day
Trial: NCT01103037
Drug: QAV680 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to QAV680 5 capsules four times per day
Trial: NCT02730689
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00968383
Drug: Platelet inhibitors
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive platelet inhibitors.
Trial: NCT00968383
Drug: ACE inhibitors and/or ARB and/or AA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ACE inhibitors and/or ARB and/or AA
Trial: NCT01604187
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
Trial: NCT01604187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
Trial: NCT00412997
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00673361
Drug: Concurrent decrescendo biochemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Temozolomide: 200mg/m\^2, daily, PO, days 1-4~* Vinblastine: 1.5mg/m\^2, daily, IV, days 1-4~* Cisplatin: 20mg/m\^2, daily IV, days 1-4~* IL (interleukin)-2: - 18 milli-International unit (MIU)/m\^2, IVCI (intravenous continual infusion), day 1~* 9 MIU/m\^2, IVCI, day 2~* 4.5 MIU/m\^2, IVCI, days 3 \& 4~* Interferon (IFN) alpha: 5 MIU/m\^2, daily, SC (subcutaneously), days 1-5~* 5-day inpatient regimen, to be repeated every 21 days
Trial: NCT02770170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00829413
Drug: SonoVue®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue (2.4 mL)
Trial: NCT02670434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 12 weeks
Trial: NCT03691935
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
Trial: NCT03382106
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo manufactured to look like Sildenafil 20 MG
Trial: NCT00535522
Drug: TAK-285 Recommended Phase 2 Dosing Cohort
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
Trial: NCT03522922
Drug: Topical Vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application
Trial: NCT01075763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
Trial: NCT00122096
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03182179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is taken orally BD
Trial: NCT03181893
Drug: Placebo Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
Trial: NCT00957983
Drug: BGC20-1531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration followed by Prostaglandin E2 infusion
Trial: NCT03439787
Drug: Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution
RxNorm normalized name: bupivacaine-epinephrine 0.5%-1:200,000 injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml
Trial: NCT02656914
Drug: Irlanda-2-Association
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 10 mL every 12 hours (2x/day), oral route.
Trial: NCT02656914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 10 mL every 12 hours (2x/day), oral route.
Trial: NCT01219673
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by mouth twice a day.
Trial: NCT02009306
Drug: Standard subcutaneous medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous as needed medication will include:~* Opioids for pain or dyspnoea~  * Diamorphine~ * Oxycodone~ * Fentanyl~* Benzodiazepine and / or anti-psychotic for agitation~  * Midazolam~ * Levomepromazine~ * Haloperidol Anti-emetic for nausea~* Cyclizine~* Metoclopramide~* Haloperidol~* Levomepromazine~* Anti-secretory drug for respiratory secretions~* Glycopyrronium~* Hyoscine butylbromide~* Hyoscine hydrobromide
Trial: NCT01393223
Drug: LP-08 80mg
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of 80mg LP08
Trial: NCT01393223
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of normal saline
Trial: NCT01393223
Drug: LP-08 20mg
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of 20mg LP08
Trial: NCT00580853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02231190
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
Trial: NCT02231190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
Trial: NCT02079948
Drug: Methotrexate + Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in the methotrexate + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression.
Trial: NCT02079948
Drug: Placebo + Folic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the placebo + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression